FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC

Oncology (Williston Park). 2020 Oct 9;34(10):406-406;431. doi: 10.46883/ONC.2020.3410.0406.

Abstract

The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.

Publication types

  • Review

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Drug Approval*
  • Gene Fusion*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Proto-Oncogene Proteins c-ret / genetics*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents
  • Pyrazoles
  • Pyridines
  • Pyrimidines
  • pralsetinib
  • Proto-Oncogene Proteins c-ret
  • RET protein, human